Johnson & Johnson Wins EU Approval for Teclistamab Combo in Myeloma

Johnson & Johnson's European Commission approval of teclistamab plus daratumumab for relapsed/refractory multiple myeloma (RRMM) as early as second line reshapes the biologics supply and regulatory calculus for combination immunotherapy regimens across the EU market. The indication extension, granted August 21, 2026, moves a BCMAxCD3 bispecific antibody into earlier lines of therapy, a shift that carries direct consequences for cold-chain infrastructure, batch release scheduling, and GMP-compliant co-administration protocols at treatment centres.

The approval is supported by Phase 3 MajesTEC-3 data (NCT05083169), which evaluated teclistamab plus daratumumab subcutaneous formulation against investigator's choice of DPd or DVd in patients with one to three prior lines of therapy. The study demonstrated statistically significant improvements in both progression-free survival and overall survival versus standard-of-care regimens. Notably, more than 90% of patients who were progression-free at six months remained progression-free at three years, a durability profile that underpins the second-line positioning and will inform label expectations across comparable regulatory submissions.

For QA directors and supply chain leads, the combination regimen introduces layered complexity. Teclistamab, a bispecific antibody requiring subcutaneous delivery, and daratumumab SC must each meet independent sterility assurance and cold-chain requirements under 21 CFR Part 211 equivalents within EU GMP frameworks. Scaling concurrent production and distribution of two biologics to meet anticipated second-line demand, a substantially larger patient population than later-line use, will test existing capacity planning assumptions and supplier qualification timelines.

The complementary mechanism is clinically relevant to the regulatory read: daratumumab modulates the immune environment to enhance T-cell fitness, amplifying teclistamab-mediated tumour cell killing. This mechanistic rationale was central to the MajesTEC-3 trial design and will likely inform how the European Medicines Agency frames future combination biologic submissions under ICH Q10 lifecycle management principles, particularly around post-approval change management for either component.

Regulatory affairs leads tracking the EU combination biologic pathway should note that this approval establishes a precedent for bispecific-plus-monoclonal antibody doublets at earlier treatment lines, with Phase 3 OS data as the evidentiary standard. Submissions for analogous regimens will face that benchmark directly.

The MajesTEC-3 overall survival data, published in The New England Journal of Medicine in 2025, will serve as the reference dataset against which subsequent RRMM combination regimens are measured in European regulatory review.

Source: Johnson & Johnson via GlobeNewswire, August 21, 2026.